Previous 10 | Next 10 |
Icon (ICLR): Q3 GAAP EPS of $1.72 beats by $0.12.Revenue of $701.73M (-1.2% Y/Y) beats by $31.63M.Raising FY 2020 revenue guidance to a range of $2,750-$2,810M and EPS in the range of $6.35-$6.50.Shares +4.83%.Press Release For further details see: Icon EPS beats by $0.12, beats on reve...
Highlights Record net business wins in the quarter of $990 million; a book to bill of 1.41. Record closing backlog of $9.4 billion, an increase of 11.8% year on year. Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and ...
Icon (NASDAQ:ICLR) is scheduled to announce Q3 earnings results on Wednesday, October 21st, after market close.The consensus EPS Estimate is $1.57 (-9.8% Y/Y) and the consensus Revenue Estimate is $670.1M (-5.7% Y/Y).Over the last 2 years, ICLR has beaten EPS estimates 50% of the time and has...
Award recognises ICON’s long-standing vaccine development expertise ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government a...
Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biote...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that: Mr. Brendan Brennan, CFO of ICON plc, will present...
ICON recognised as top employer for women in anonymous survey of 75,000 employees ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been...
Any potential coronavirus treatment or vaccine could run through ICON ( ICLR ), a large clinical-research organization (CRO) that helps pharmaceutical companies develop new medications, asserts Richard Moroney , editor of Dow Theory Forecasts . The company focuses on lat...
Investment Thesis Icon PLC 5-year share price performance. Source: TradingView. Icon ( ICLR ) looks like a solid investment opportunity in the contract research organization ("CRO") space, offering strong growth potential whilst being a little undervalued by the market, based on my anal...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...